sur Galimedix, Inc.
Galimedix Forms Advisory Board to Guide Alzheimer's Drug Development
Galimedix Therapeutics, Inc. has announced the creation of a Scientific Advisory Board (SAB) dedicated to advancing GAL-101, a novel drug candidate for Alzheimer’s disease. This board includes global experts in Alzheimer's biology, biomarkers, cognitive assessment, and drug development. The aim is to support the clinical development of GAL-101, which acts as a modulator of amyloid beta aggregation, a key therapeutic target in Alzheimer’s.
The SAB will provide guidance on scientific and clinical strategy as Galimedix prepares for its Phase 2a SAPHARY study. This follows successful Phase 1 trials that reported excellent safety and tolerability of GAL-101, with evidence of blood-brain barrier penetration.
Galimedix is also developing GAL-301 as another potential treatment in its Alzheimer’s pipeline, while continuing efforts in ophthalmology research. The newly established board is expected to be a crucial part of the development and potential success of these innovative therapies.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galimedix, Inc.